Patents by Inventor Jason Lohmueller

Jason Lohmueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF TIM-3 CYTOPLASMIC TAIL IN CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20240122980
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) that include (a) an extracellular scFv comprising a light chain variable domain (VL) a heavy chain variable domain (VH), wherein the scFv specifically binds to an antigen of interest; (b) a CD8 hinge domain and transmembrane domain; and (c) a cytoplasmic domain comprising (i) a TIM-3 cytoplasmic domain and an intracellular signaling domain, wherein (a)-(c) are in N-terminal to C-terminal order. Also disclosed are nucleic acid molecules encoding these CARs, host cells transformed with these nucleic acids, and the use of these compositions for treating a subject, such as a subject with a tumor.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 18, 2024
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Lawrence Patrick Kane, Jason Lohmueller
  • AFFINITY-ENHANCED MONMERIC STREPTAVIDIN CHIMERIC ANTIGEN RECEPTOR (CAR)
    Publication number: 20210371476
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin; (b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Application
    Filed: August 10, 2021
    Publication date: December 2, 2021
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller
  • Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
    Patent number: 11117936
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Pittsburg—Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller
  • MSA2 AFFINITY-ENHANCED BIOTIN-BINDING CHIMERIC ANTIGEN RECEPTOR (CAR)
    Publication number: 20190161520
    Abstract: A chimeric antigen receptor is disclosed that includes: (a) an extracellular high affinity streptavidin;(b) a hinge domain from CD8; (c) a CD28 transmembrane domain; (d) an intracellular 4-1BB and/or CD28 signaling domain; and (e) an intracellular CD3 zeta signaling domain, wherein (a)-(e) are in N-terminal to C-terminal order. Nucleic acids encoding this chimeric antigen receptor, and T and natural killer (NK) cells transformed with this chimeric antigen receptor are also disclosed. The use of this chimeric antigen receptor for the treatment of tumors is also disclosed.
    Type: Application
    Filed: November 7, 2018
    Publication date: May 30, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Jason Lohmueller